Seer(US:SEER) Globenewswire·2026-02-26 21:05Core Insights - Seer, Inc. reported financial results for Q4 and full year 2025, highlighting a challenging year due to budgetary pressures and NIH funding uncertainty, but noted significant progress in business growth and product adoption [3][4]. Financial Performance - Q4 2025 revenue was $4.2 million, a 5% increase from $4.0 million in Q4 2024, driven by higher product revenue [4]. - Full year 2025 revenue reached $16.6 million, a 17% increase from $14.2 million in 2024, attributed to increased product sales and service revenue [7]. - Gross profit for Q4 2025 was $2.2 million with a gross margin of 52%, while for the full year, gross profit was $8.5 million with a gross margin of 51% [5][8]. - Operating expenses for Q4 2025 were $19.6 million, a 23% decrease from $25.5 million in Q4 2024, primarily due to reduced stock-based compensation and other costs [5]. - The net loss for Q4 2025 was $16.0 million, an improvement from a net loss of $21.7 million in the same period of the previous year [6]. Business Growth and Developments - The installed base of instruments grew to 82, representing a 67% year-over-year increase, with 33 instruments installed during 2025 [10]. - Seer’s Proteograph was selected for multiple population-scale studies, and significant customer studies were published in reputable journals, showcasing its capabilities [3][10]. - The company ended 2025 with approximately $240.6 million in cash, cash equivalents, and investments [11]. Future Outlook - For 2026, Seer expects revenue to be in the range of $16 million to $18 million, indicating a projected growth of approximately 3% at the midpoint compared to 2025 [12].